Delivery Order SPE2DR25D1034-SPE2DR26FPV8W
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $9,353.44 firm fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on July 21, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The delivery order, which represents a non-competitive set-aside award, is scheduled for completion by July 22, 2025, with performance occurring at the vendor's Conshohocken facility. This delivery order is issued...
- AmerisourceBergen Drug Corp was awarded a delivery order on April 24, 2025, valued at $6,707.89 for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order is set to be completed by April 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was issued by the Medical Supply Chain division of the Defense Logistics Agency under the federal government's medical procurement...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,976.49 by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract operates under firm fixed-price terms with an ultimate completion date of September 29, 2025, and represents a non-set-aside, competitively awarded procurement. This delivery order is executed as a child contract under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,633.44 for NovoLog 100 Unit/ML FlexPen 3ML insulin pens on November 10, 2025, with an ultimate completion date of November 12, 2025. This non-competitive, firm fixed-price delivery order will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 30, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with a ceiling value of $1,354.88 and an ultimate completion date of July 31, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.62 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $1,254.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of November 4, 2025. This non-set-aside competitive award was issued on November 3, 2025, with the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a single transaction within the company's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,204.12 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. Issued on August 27, 2025, this firm fixed price delivery order is scheduled for completion by August 28, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under a larger contract vehicle and reflects the...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively as a child contract under AmerisourceBergen's larger DLA prime vendor contract vehicle. The place of performance is listed as...
- SPE2DR25D1034Indefinite Delivery Contract
- SPE2DR25D1034-SPE2DR26FPV8WDelivery Order
AmerisourceBergen Drug Corp was awarded a $2,361.39 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on November 14, 2025, for the supply of NovoLog Penfill 100 Unit/ML 3ML insulin pens. This non-set-aside award is scheduled for completion by November 17, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's critical role as a pharmaceutical supplier to the federal government, particularly supporting military and veteran healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As the prime contractor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies an extensive range of medications and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The award of this insulin delivery order demonstrates the company's ongoing capability to fulfill federal medical procurement requirements through competitive processes and its significance as a key vendor within the Defense Health Agency's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 11/14/25 |